Insider Buying: Tempest Therapeutics, Inc. (NASDAQ:TPST) CEO Acquires $73,850.00 in Stock

Tempest Therapeutics, Inc. (NASDAQ:TPSTGet Free Report) CEO Stephen R. Brady purchased 35,000 shares of Tempest Therapeutics stock in a transaction that occurred on Wednesday, July 3rd. The stock was acquired at an average price of $2.11 per share, with a total value of $73,850.00. Following the transaction, the chief executive officer now owns 46,376 shares in the company, valued at $97,853.36. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Tempest Therapeutics Stock Performance

Shares of TPST stock opened at $2.15 on Thursday. The company has a current ratio of 3.13, a quick ratio of 3.13 and a debt-to-equity ratio of 0.20. The stock has a 50 day simple moving average of $2.92 and a 200-day simple moving average of $3.55. The company has a market cap of $47.77 million, a price-to-earnings ratio of -1.25 and a beta of -1.73. Tempest Therapeutics, Inc. has a 12-month low of $0.17 and a 12-month high of $9.77.

Tempest Therapeutics (NASDAQ:TPSTGet Free Report) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.08. On average, equities analysts forecast that Tempest Therapeutics, Inc. will post -1.57 EPS for the current year.

Wall Street Analyst Weigh In

TPST has been the topic of a number of recent research reports. Scotiabank started coverage on shares of Tempest Therapeutics in a research note on Thursday, March 14th. They issued a “sector outperform” rating and a $13.00 price objective on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $8.00 price objective on shares of Tempest Therapeutics in a research note on Friday, June 21st. HC Wainwright reaffirmed a “buy” rating and set a $47.00 price objective on shares of Tempest Therapeutics in a research report on Thursday, June 20th. Finally, William Blair reissued an “outperform” rating on shares of Tempest Therapeutics in a report on Wednesday, March 20th. Five investment analysts have rated the stock with a buy rating, According to, the company presently has an average rating of “Buy” and an average target price of $20.75.

Check Out Our Latest Analysis on TPST

Institutional Trading of Tempest Therapeutics

An institutional investor recently raised its position in Tempest Therapeutics stock. Virtu Financial LLC grew its stake in shares of Tempest Therapeutics, Inc. (NASDAQ:TPSTFree Report) by 69.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 28,574 shares of the company’s stock after acquiring an additional 11,689 shares during the period. Virtu Financial LLC owned about 0.13% of Tempest Therapeutics worth $112,000 at the end of the most recent reporting period. Institutional investors own 22.52% of the company’s stock.

Tempest Therapeutics Company Profile

(Get Free Report)

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.

Recommended Stories

Receive News & Ratings for Tempest Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempest Therapeutics and related companies with's FREE daily email newsletter.